CMRES
MCID: CMR002
MIFTS: 52

Coumarin Resistance (CMRES)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Coumarin Resistance

MalaCards integrated aliases for Coumarin Resistance:

Name: Coumarin Resistance 58 26 76 38 13 74
Warfarin Resistance 58 54 26 76 56
Warfarin Sensitivity 58 54 26 74
Warfarin Response 26 30 6
Poor Metabolism of Coumarin 26 76
Coumadin Sensitivity 54 26
Coumarin, Poor Metabolism of 58
Drug Resistance 45
Cmres 76

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
coumarin resistance:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 58 122700
KEGG 38 H01205
MeSH 45 D004351
SNOMED-CT via HPO 70 191124002 263681008 34093004

Summaries for Coumarin Resistance

NIH Rare Diseases : 54 Warfarin resistance is a condition that is characterized by a high tolerance for a "blood-thinning" medication called warfarin. Warfarin is an anticoagulant that is often prescribed to people who are at an increased risk for blood clots. Some people with a warfarin resistance do not respond to the drug at all, while others can achieve the benefits of warfarin treatment at a high dose. In either case, affected people will still be at an elevated risk for blood clots when given the standard dose of warfarin. The metabolism of warfarin and the drug's effects in the body are complex traits that are determined by several genes as well as environmental and lifestyle factors such as gender, age, weight, diet, and other medications. One specific genetic polymorphism in the VKORC1 gene accounts for approximately 20% of variation in the response to warfarin and can be passed on to future generations in an autosomal dominant manner.

MalaCards based summary : Coumarin Resistance, also known as warfarin resistance, is related to atrial fibrillation and multidrug-resistant tuberculosis. An important gene associated with Coumarin Resistance is VKORC1 (Vitamin K Epoxide Reductase Complex Subunit 1), and among its related pathways/superpathways are Drug metabolism - cytochrome P450 and Arachidonic acid metabolism. The drugs Warfarin and Phenprocoumon have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and breast, and related phenotypes are abnormality of metabolism/homeostasis and abnormality of blood and blood-forming tissues

Genetics Home Reference : 26 Warfarin sensitivity is a condition in which individuals have a low tolerance for the drug warfarin. Warfarin is an anticoagulant, which means that it thins the blood, preventing blood clots from forming. Warfarin is often prescribed to prevent blood clots in people with heart valve disease who have replacement heart valves, people with an irregular heart beat (atrial fibrillation), or those with a history of heart attack, stroke, or a prior blood clot in the deep veins of the arms or legs (deep vein thrombosis).

OMIM : 58 Warfarin is a widely prescribed anticoagulant for the prevention of thromboembolic diseases for subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement (Yuan et al., 2005). The dose requirement is highly variable, both interindividually and interethnically. Variation in the VKORC1 gene is believed to be the most important individual predictor of warfarin dose, accounting for about 30% of the variance observed in dosing (Ross et al., 2010). (122700)

CDC : 3 Antibiotic resistance is one of the biggest public health challenges of our time. Each year in the U.S., at least 2 million people get an antibiotic-resistant infection, and at least 23,000 people die. Fighting this threat is a public health priority that requires a collaborative global approach across sectors. CDC is working to combat this threat. Find out how you can help.

UniProtKB/Swiss-Prot : 76 Coumarin resistance: A condition characterized by partial or complete resistance to warfarin or other 4-hydroxycoumarin derivatives. These drugs are used as anti-coagulants for the prevention of thromboembolic diseases in subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement.

Related Diseases for Coumarin Resistance

Diseases related to Coumarin Resistance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 560)
# Related Disease Score Top Affiliating Genes
1 atrial fibrillation 29.0 CYP4F2 VKORC1
2 multidrug-resistant tuberculosis 11.5
3 mycobacterium abscessus 11.4
4 ceroid lipofuscinosis, neuronal, 2 11.0
5 leukodystrophy, hypomyelinating, 14 11.0
6 epilepsy occipital calcifications 11.0
7 epilepsy 10.8
8 leukemia 10.7
9 breast cancer 10.7
10 mycobacterium tuberculosis 1 10.7
11 ovarian cancer 10.6
12 human immunodeficiency virus type 1 10.6
13 lung cancer 10.6
14 focal epilepsy 10.5
15 pulmonary tuberculosis 10.5
16 myeloma, multiple 10.5
17 malaria 10.5
18 myeloid leukemia 10.5
19 hepatitis 10.4
20 lymphocytic leukemia 10.4
21 gastric cancer 10.4
22 temporal lobe epilepsy 10.4
23 small cell cancer of the lung 10.4
24 hepatocellular carcinoma 10.4
25 leukemia, acute myeloid 10.4
26 lymphoma 10.4
27 colorectal cancer 10.4
28 leukemia, acute lymphoblastic 10.3
29 typhoid fever 10.3
30 melanoma 10.3
31 pneumonia 10.3
32 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.3
33 ovarian cancer 1 10.3
34 meningitis 10.3
35 hepatitis b 10.3
36 pancreatic cancer 10.3
37 hepatitis c 10.3
38 plasmodium falciparum malaria 10.3
39 hypoxia 10.3
40 leprosy 3 10.2
41 osteogenic sarcoma 10.2
42 hepatitis c virus 10.2
43 noonan syndrome 3 10.2
44 hansen's disease 10.2
45 glioblastoma 10.2
46 human immunodeficiency virus infectious disease 10.2
47 influenza 10.2
48 burns 10.2
49 glioma 10.2
50 leukemia, chronic lymphocytic 2 10.2

Graphical network of the top 20 diseases related to Coumarin Resistance:



Diseases related to Coumarin Resistance

Symptoms & Phenotypes for Coumarin Resistance

Human phenotypes related to Coumarin Resistance:

33
# Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 33 HP:0001939
2 abnormality of blood and blood-forming tissues 33 HP:0001871

Symptoms via clinical synopsis from OMIM:

58
Heme:
warfarin resistance

Lab:
decreased affinity of liver receptors for coumarin

Clinical features from OMIM:

122700

GenomeRNAi Phenotypes related to Coumarin Resistance according to GeneCards Suite gene sharing:

27 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.5 F9
2 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.5 F9
3 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.5 CYP2C9
4 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.5 F9
5 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.5 CYP2C9 F9
6 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.5 CYP2C9
7 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.5 CYP2C9
8 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.5 F9
9 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.5 F9
10 Increased shRNA abundance (Z-score > 2) GR00366-A-44 9.5 F9
11 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.5 CYP2C9
12 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.5 CYP2C9
13 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.5 F9
14 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.5 F9

Drugs & Therapeutics for Coumarin Resistance

Drugs for Coumarin Resistance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Warfarin Approved Phase 4 81-81-2 54678486 6691
2
Phenprocoumon Approved, Investigational Phase 4 435-97-2 54680692 9908
3
Acenocoumarol Approved, Investigational Phase 4 152-72-7 54676537 9052
4 Anticoagulants Phase 4

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin Completed NCT01119300 Phase 4
2 EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon Completed NCT01119274 Phase 4
3 EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol Completed NCT01119261 Phase 4

Search NIH Clinical Center for Coumarin Resistance

Cochrane evidence based reviews: drug resistance

Genetic Tests for Coumarin Resistance

Genetic tests related to Coumarin Resistance:

# Genetic test Affiliating Genes
1 Warfarin Response 30 CYP2A6 CYP2C9 F9 VKORC1

Anatomical Context for Coumarin Resistance

MalaCards organs/tissues related to Coumarin Resistance:

42
Heart, Lung, Breast, T Cells, Liver, Myeloid, B Cells

Publications for Coumarin Resistance

Articles related to Coumarin Resistance:

(show top 50) (show all 125)
# Title Authors Year
1
Warfarin resistance from primidone in patient with essential tremor. ( 29170795 )
2018
2
Low warfarin resistance frequency in Norway rats in two cities in China after 30 years of usage of anticoagulant rodenticides. ( 29667309 )
2018
3
Anticoagulation therapy for a LVAD patient with acquired warfarin resistance. ( 28349222 )
2017
4
VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance. ( 24978953 )
2016
5
Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling. ( 26513304 )
2016
6
Warfarin resistance due to VKORC1 gene mutation in a patient following mechanical aortic valve replacement with an ON-X valve. ( 25885753 )
2015
7
Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. ( 26186657 )
2015
8
Comparative genetics of warfarin resistance. ( 24287886 )
2014
9
Confirmation of warfarin resistance of naturally occurring VKORC1 variants by coexpression with coagulation factor IX and in silico protein modelling. ( 24491178 )
2014
10
A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay. ( 23452238 )
2013
11
Possible warfarin resistance due to interaction with ascorbic acid: case report and literature review. ( 23592361 )
2013
12
Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells. ( 23710884 )
2013
13
C3435T polymorphism of MDR1 gene with warfarin resistance. ( 23872171 )
2013
14
Do pharmacogenetics have a role in the dosing of vitamin K antagonists? ( 24251364 )
2013
15
Warfarin resistance and caffeine containing beverages. ( 21852006 )
2012
16
Warfarin resistance associated with parenteral nutrition. ( 22143126 )
2012
17
Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic. ( 22266406 )
2012
18
Lipid solubility of warfarin may contribute to warfarin resistance in patients receiving total parenteral nutrition. ( 22996140 )
2012
19
Exacerbation of hereditary warfarin resistance by azathioprine. ( 20211925 )
2011
20
More on: endoplasmic reticulum loop VKORC1 substitutions cause warfarin resistance but do not diminish gamma-carboxylation of the vitamin K-dependent coagulation factors. ( 21362126 )
2011
21
An instructive case suggesting warfarin resistance which is independent on the regulation of the CYP2C9 and VKORC1 genotype. ( 22338910 )
2011
22
Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. ( 20555338 )
2010
23
Warfarin resistance induced by oxcarbamazepine. ( 19666450 )
2009
24
Malabsorption-associated warfarin resistance. ( 19710438 )
2009
25
An algorithm for managing warfarin resistance. ( 19952297 )
2009
26
A vitamin K epoxide reductase complex subunit 1 mutation in an Irish patient with warfarin resistance. ( 18266023 )
2008
27
Vitamin K-independent warfarin resistance after concurrent administration of warfarin and continuous enteral nutrition. ( 18294110 )
2008
28
VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. ( 18362220 )
2008
29
Azathioprine-induced warfarin resistance. ( 18505911 )
2008
30
Warfarin resistance and enteral tube feeding: a vitamin K-independent interaction. ( 18602249 )
2008
31
Warfarin resistance. ( 18776969 )
2008
32
Assaying of warfarin in Iranian warfarin resistance patients blood by HPLC. ( 18817151 )
2008
33
Warfarin resistance after total gastrectomy and Roux-en-Y esophagojejunostomy. ( 19025435 )
2008
34
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. ( 18855533 )
2008
35
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. ( 18281922 )
2008
36
A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. ( 18281915 )
2008
37
Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. ( 18252229 )
2008
38
A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. ( 17110455 )
2007
39
Early mechanical mitral valve thrombosis in a patient with warfarin resistance. ( 17484471 )
2007
40
Inherited warfarin resistance in Indian patients: does it occur? ( 17636200 )
2007
41
Inherited warfarin resistance in Indian patients: does it occur? ( 17911202 )
2007
42
Warfarin resistance: interaction between warfarin and Eruca sativa L. ( 16741856 )
2006
43
Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. ( 16611750 )
2006
44
Warfarin resistance in a patient with mechanical valve prosthesis. ( 15770320 )
2005
45
Warfarin resistance in a French strain of rats. ( 16421894 )
2005
46
A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. ( 15888487 )
2005
47
CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. ( 15714076 )
2005
48
Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. ( 15805193 )
2005
49
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. ( 14765194 )
2004
50
Warfarin resistance with poor CYP2C9 activity and CYP2C9*1*2 genotype. ( 15039471 )
2004

Variations for Coumarin Resistance

UniProtKB/Swiss-Prot genetic disease variations for Coumarin Resistance:

76 (show all 18)
# Symbol AA change Variation ID SNP ID
1 VKORC1 p.Val29Leu VAR_021821 rs104894539
2 VKORC1 p.Val45Ala VAR_021822 rs104894540
3 VKORC1 p.Arg58Gly VAR_021823 rs104894541
4 VKORC1 p.Leu128Arg VAR_021825 rs104894542
5 VKORC1 p.Ala26Thr VAR_065785 rs770703948
6 VKORC1 p.Asp36Gly VAR_065786
7 VKORC1 p.Asp36Tyr VAR_065787 rs61742245
8 VKORC1 p.Ser52Trp VAR_065788
9 VKORC1 p.Ser56Phe VAR_065789
10 VKORC1 p.Trp59Cys VAR_065790
11 VKORC1 p.Trp59Leu VAR_065791
12 VKORC1 p.Val66Gly VAR_065792
13 VKORC1 p.Val66Met VAR_065793 rs72547529
14 VKORC1 p.Gly71Ala VAR_065794
15 VKORC1 p.Asn77Ser VAR_065795
16 VKORC1 p.Asn77Tyr VAR_065796 rs755767348
17 VKORC1 p.Ile123Asn VAR_065797
18 VKORC1 p.Tyr139His VAR_065798

ClinVar genetic disease variations for Coumarin Resistance:

6 (show all 34)
# Gene Variation Type Significance SNP ID Assembly Location
1 CYP2C9 NM_000771.3(CYP2C9): c.1075A> C (p.Ile359Leu) single nucleotide variant drug response rs1057910 GRCh37 Chromosome 10, 96741053: 96741053
2 CYP2C9 NM_000771.3(CYP2C9): c.1075A> C (p.Ile359Leu) single nucleotide variant drug response rs1057910 GRCh38 Chromosome 10, 94981296: 94981296
3 CYP2C9 NM_000771.3(CYP2C9): c.430C> T (p.Arg144Cys) single nucleotide variant drug response rs1799853 GRCh37 Chromosome 10, 96702047: 96702047
4 CYP2C9 NM_000771.3(CYP2C9): c.430C> T (p.Arg144Cys) single nucleotide variant drug response rs1799853 GRCh38 Chromosome 10, 94942290: 94942290
5 CYP2C9 NM_000771.4(CYP2C9): c.622T> G (p.Leu208Val) single nucleotide variant Pathogenic rs72558191 GRCh37 Chromosome 10, 96707676: 96707676
6 CYP2C9 NM_000771.4(CYP2C9): c.622T> G (p.Leu208Val) single nucleotide variant Pathogenic rs72558191 GRCh38 Chromosome 10, 94947919: 94947919
7 F9 F9, ALA-10THR single nucleotide variant Pathogenic
8 F9 F9, ALA-10VAL undetermined variant Pathogenic
9 CYP2A6 NM_000762.5(CYP2A6): c.479T> A (p.Leu160His) single nucleotide variant drug response rs1801272 GRCh37 Chromosome 19, 41354533: 41354533
10 CYP2A6 NM_000762.5(CYP2A6): c.479T> A (p.Leu160His) single nucleotide variant drug response rs1801272 GRCh38 Chromosome 19, 40848628: 40848628
11 CYP2A6 CYP2A6*12A deletion drug response GRCh38 Chromosome 19, 40848764: 40881588
12 CYP2A6 CYP2A6*12A deletion drug response GRCh37 Chromosome 19, 41354669: 41387493
13 VKORC1 NM_024006.5(VKORC1): c.174-136C> T single nucleotide variant drug response rs9934438 GRCh37 Chromosome 16, 31104878: 31104878
14 VKORC1 NM_024006.5(VKORC1): c.174-136C> T single nucleotide variant drug response rs9934438 GRCh38 Chromosome 16, 31093557: 31093557
15 VKORC1 NM_024006.5(VKORC1): c.-226-1362dupG insertion drug response rs397509427 GRCh37 Chromosome 16, 31107638: 31107638
16 VKORC1 NM_024006.5(VKORC1): c.-226-1362dupG insertion drug response rs397509427 GRCh38 Chromosome 16, 31096317: 31096317
17 CYP2C9 NM_000771.4(CYP2C9): c.1075A= (p.Ile359=) single nucleotide variant no interpretation for the single variant rs1057910 GRCh38 Chromosome 10, 94981296: 94981296
18 CYP2C9 NM_000771.4(CYP2C9): c.1075A= (p.Ile359=) single nucleotide variant no interpretation for the single variant rs1057910 GRCh37 Chromosome 10, 96741053: 96741053
19 CYP2C9 NM_000771.4(CYP2C9): c.430C= (p.Arg144=) single nucleotide variant no interpretation for the single variant rs1799853 GRCh37 Chromosome 10, 96702047: 96702047
20 CYP2C9 NM_000771.4(CYP2C9): c.430C= (p.Arg144=) single nucleotide variant no interpretation for the single variant rs1799853 GRCh38 Chromosome 10, 94942290: 94942290
21 VKORC1 NM_024006.5(VKORC1): c.-226-1413G= single nucleotide variant drug response rs9923231 GRCh37 Chromosome 16, 31107689: 31107689
22 VKORC1 NM_024006.5(VKORC1): c.-226-1413G= single nucleotide variant drug response rs9923231 GRCh38 Chromosome 16, 31096368: 31096368
23 VKORC1 NM_024006.5(VKORC1): c.106G> T (p.Asp36Tyr) single nucleotide variant drug response rs61742245 GRCh38 Chromosome 16, 31094624: 31094624
24 VKORC1 NM_024006.5(VKORC1): c.106G> T (p.Asp36Tyr) single nucleotide variant drug response rs61742245 GRCh37 Chromosome 16, 31105945: 31105945
25 VKORC1 NM_024006.4(VKORC1): c.-1639G> A single nucleotide variant Likely benign, drug response, other rs9923231 GRCh38 Chromosome 16, 31096368: 31096368
26 VKORC1 NM_024006.4(VKORC1): c.-1639G> A single nucleotide variant Likely benign, drug response, other rs9923231 GRCh37 Chromosome 16, 31107689: 31107689
27 VKORC1 NM_024006.5(VKORC1): c.383T> G (p.Leu128Arg) single nucleotide variant drug response rs104894542 GRCh38 Chromosome 16, 31091243: 31091243
28 VKORC1 NM_024006.5(VKORC1): c.383T> G (p.Leu128Arg) single nucleotide variant drug response rs104894542 GRCh37 Chromosome 16, 31102564: 31102564
29 VKORC1 NM_024006.5(VKORC1): c.172A> G (p.Arg58Gly) single nucleotide variant Pathogenic rs104894541 GRCh38 Chromosome 16, 31094558: 31094558
30 VKORC1 NM_024006.5(VKORC1): c.172A> G (p.Arg58Gly) single nucleotide variant Pathogenic rs104894541 GRCh37 Chromosome 16, 31105879: 31105879
31 VKORC1 NM_024006.5(VKORC1): c.134T> C (p.Val45Ala) single nucleotide variant Pathogenic rs104894540 GRCh38 Chromosome 16, 31094596: 31094596
32 VKORC1 NM_024006.5(VKORC1): c.134T> C (p.Val45Ala) single nucleotide variant Pathogenic rs104894540 GRCh37 Chromosome 16, 31105917: 31105917
33 VKORC1 NM_024006.5(VKORC1): c.85G> T (p.Val29Leu) single nucleotide variant Pathogenic rs104894539 GRCh38 Chromosome 16, 31094645: 31094645
34 VKORC1 NM_024006.5(VKORC1): c.85G> T (p.Val29Leu) single nucleotide variant Pathogenic rs104894539 GRCh37 Chromosome 16, 31105966: 31105966

Expression for Coumarin Resistance

Search GEO for disease gene expression data for Coumarin Resistance.

Pathways for Coumarin Resistance

Pathways related to Coumarin Resistance according to KEGG:

38
# Name Kegg Source Accession
1 Drug metabolism - cytochrome P450 hsa00982

Pathways related to Coumarin Resistance according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.72 CYP2C9 CYP4F2
2
Show member pathways
11.56 CYP2C9 CYP4F2
3
Show member pathways
11.28 CYP2A6 CYP2C9
4
Show member pathways
11.05 CYP2A6 CYP2C9
5 10.94 CYP2A6 CYP2C9
6
Show member pathways
10.88 CYP2A6 CYP2C9
7
Show member pathways
10.8 CYP2C9 CYP4F2
8 10.7 CYP2A6 CYP2C9
9 10.58 CYP2A6 CYP2C9
10 10.46 CYP2A6 CYP2C9
11 10.07 CYP2A6 CYP2C9
12 9.98 CYP4F2 F9 VKORC1

GO Terms for Coumarin Resistance

Cellular components related to Coumarin Resistance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular membrane-bounded organelle GO:0043231 9.56 CYP2A6 CYP2C9 CYP4F2 VKORC1
2 endoplasmic reticulum GO:0005783 9.55 CYP2A6 CYP2C9 CYP4F2 MCFD2 VKORC1
3 organelle membrane GO:0031090 9.13 CYP2A6 CYP2C9 CYP4F2
4 endoplasmic reticulum membrane GO:0005789 9.02 CYP2A6 CYP2C9 CYP4F2 MCFD2 VKORC1

Biological processes related to Coumarin Resistance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.62 CYP2A6 CYP2C9 CYP4F2 VKORC1
2 steroid metabolic process GO:0008202 9.46 CYP2A6 CYP2C9
3 xenobiotic metabolic process GO:0006805 9.43 CYP2A6 CYP2C9
4 blood coagulation GO:0007596 9.43 CYP4F2 F9 VKORC1
5 exogenous drug catabolic process GO:0042738 9.4 CYP2A6 CYP2C9
6 organic acid metabolic process GO:0006082 9.37 CYP2A6 CYP2C9
7 omega-hydroxylase P450 pathway GO:0097267 9.16 CYP2C9 CYP4F2
8 epoxygenase P450 pathway GO:0019373 9.13 CYP2A6 CYP2C9 CYP4F2
9 drug metabolic process GO:0017144 8.92 CYP2A6 CYP2C9 CYP4F2 VKORC1

Molecular functions related to Coumarin Resistance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 9.85 CYP2A6 CYP2C9 CYP4F2 F9 MCFD2
2 oxidoreductase activity GO:0016491 9.62 CYP2A6 CYP2C9 CYP4F2 VKORC1
3 monooxygenase activity GO:0004497 9.43 CYP2C9 CYP4F2
4 heme binding GO:0020037 9.43 CYP2A6 CYP2C9 CYP4F2
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.4 CYP2A6 CYP2C9
6 steroid hydroxylase activity GO:0008395 9.37 CYP2A6 CYP2C9
7 iron ion binding GO:0005506 9.33 CYP2A6 CYP2C9 CYP4F2
8 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.13 CYP2A6 CYP2C9 CYP4F2
9 arachidonic acid epoxygenase activity GO:0008392 8.8 CYP2A6 CYP2C9 CYP4F2

Sources for Coumarin Resistance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....